Skin tests to check biotherapy allergies in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study uses drug skin testing to explore potential allergic reactions to biotherapies used in cancer treatment. Participants have received at least two doses of specified biotherapies and do not have suspected allergic side effects. The goal is to better characterize allergic responses and improve safety in the use of these biological therapies. The trial is conducted at CHU Angers under the lead sponsorship of the University Hospital, Angers. No results or data on outcomes are provided in this description.

Why it matters

Who can join: the full rules

Inclusion Criteria :

* Patient treated with one of the biotherapies under study (Atezolizumab 1200 mg, Nivolumab 480 mg, Obinutuzumab 100 mg, Durvalumab 1500 mg, Pembrolizumab 200 mg, Daratumumab 1800 mg, Cemiplimab 3500 mg) and who has received at least two injections of the biotherapy without suspected allergic side effects.
* Subjects covered by or having the rights to medical care assurance
* Written informed consent obtained from subject
* If applicable, treatment with corticosteroids and H1 antihistamines by systemic route (IV or oral) which may be discontinued at least one week before performing the tests (Inhaled corticosteroids are allowed).

Exclusion Criteria:

* Presence of local or diffuse dermatological lesions (e.g., psoriasis, eczema, ...) that could interfere with the interpretation of skin tests.
* Poor understanding of the French language
* Pregnancy, breastfeeding
* Persons in detention by judicial or administrative decision
* Person admitted to a health or social establishment for purposes other than research
* Person subject to a legal protection measure

Where it's running

• CHU Angers
  Angers, France Recruiting

Study contacts

• Principal investigator: Martine MORISSET — University Hospital, Angers
• Study coordinator: Martine MORISSET
• Email: martine.morisset@chu-angers.fr
• Phone: 02 41 35 36 37

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chemotherapy-related thinking and memory changes during treatment for blood cancers

  This project will follow adults with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma who are receiving first-line fixed-duration chemotherapy to see how common and how severe chemotherapy-related thinking and memory problems are compared with a close relative.

  Recruiting University Hospital, Angers · Angers, Maine et Loire · NCT07147621

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• Breath test to help detect gastrointestinal cancers early

  A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.

  Recruiting Imperial College London · Maidstone, Kent and 5 other locations · NCT07714538

• KRAS G12V cancer patients get TCR1188-ABC cell therapy

  This early-phase trial tests whether TCR1188-ABC cells can safely be given to adults with KRAS G12V-mutated metastatic cancers to see if it can help some types of pancreatic, biliary, colorectal, or lung cancer.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07594067

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.